window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 14, 2025

  • News
  • About Us
Contact Us

Biotech News

  • Cell & Gene Therapy,Clinical Development,Regulatory Affairs

    Nanoscope Therapeutics begins FDA submission for gene-agnostic therapy to treat retinitis pigmentosa

    Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]

    July 15, 2025
  • Clinical Trials,Partnerships & Funding,Patient Centricity,Regulatory Affairs,Technology and platforms

    Cybin teams up with Osmind to advance Phase 3 psychedelic therapy for depression

    As psychedelic-assisted therapies move closer to mainstream psychiatric care, Cybin, [...]

    June 2, 2025
  • Cell & Gene Therapy

    Powerhouse partnership targets faster path to gene therapies

    eXmoor Pharma and KU Leuven team up to launch CGT [...]

    May 13, 2025
  • Clinical Trials

    Novadip’s ‘off-the-shelf’ spine fusion product shows early efficacy and safety in studies

    April 24, 2025
  • Movers & Shakers

    Terumo BCT appoints Patrick Daly as chief business officer to drive unified growth strategy

    April 24, 2025
  • Clinical Trials

    CluePoints’ time similarity test shortlisted for Citeline award for clinical trial innovation

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top